Renal cell carcinoma (RCC) with sarcomatoid features (sRCC) is an aggressive cancer that comprises approximately 5% of all RCC patients, including an estimated 10%-20% of patients with advanced disease.1-3 Although the presence of sarcomatoid features is known to be an independent predictor of poor survival, previous clinical trial data assessing the role of immunotherapy in sRCC remain sparse, leaving patients with limited therapeutic options.2-7 The dual immunotherapy combination of nivolumab (NIVO), a programmed death 1 immune checkpoint inhibitor antibody, plus ipilimumab (IPI), an anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, is approved for the first-line treatment of patients with advanced RCC and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate/poor (I/P) risk.8 This post hoc subgroup analysis examined the efficacy and safety of NIVO+IPI versus sunitinib (SUN) in patients with sRCC and I/P-risk disease included in the Phase III CheckMate 214 trial.